DermTech: demand to strengthen pharma partnerships over next 5 years
DermTech develops non-invasive gene expression tests to support skin cancer diagnosis, assess inflammatory diseases, and personalize drug treatment.
The company’s technology enables the analysis of skin biopsy samples collected non-invasively using an adhesive patch.
Dr. Burkhard Jansen, Chief Medical Officer at DermTech, told Outsourcing-Pharma.com, “An increasing number of pharma and large biotech partners are recognizing the value Dermtech’s non-invasive gene expression platform offers to their development efforts through molecular dermatology.”
In Q1 of 2017, the company has added three new “large” partnerships, Jansen explained.
“Existing partners generally add programs and expand the scope of projects after they see the extent of what the platform can offer,” he added.
The collaborations have generally entailed non-invasive tissue collection and gene expression analyses for various skin conditions, with and without systemic or topical therapeutic intervention.
Per the company's website, current clinical collaborations include MedImmune, Biogen, and Johnsons & Johnson, among others.
“While our pharma relationships expand, we are also seeing increasing interest from small to midsize biotech companies and from NGO partners,” said Jansen.
“We expect the continuing demand for personalized, precision medicine to further strengthen DermTech’s pharma partnerships over the next five years.”
